

Generic Drug Index ■ ANTINEOPLASTICS, BIOLOGICS, ANTIEMETICS, AND SUPPORTIVE CARE DRUGS

| AGENT/Indication(s) | ICD-9 Code(s) | AGENT/Indication(s) | ICD-9 Code(s) |
|---|---|---|-------------------------------------|
| Abarelix (Plenaxis) | | Bevacizumab (Avastin) | |
| Prostate | 185._ | Colorectal | 153._, 154._ |
| Abraxane | | Lung (non-small cell, non-squamous) | 162._ |
| Breast | 174._, 175._ | Bexarotene (Targetin) | |
| Aldesleukin (Proleukin) | | Cutaneous T-Cell Lymphoma | 202.1._, 202.2._, 202.8._ |
| Acute Myelogenous Leukemia ^{3XX} | 205.0_ | Bicalutamide (Casodex) | |
| Kidney | 189.0, 189.1 | Prostate | 185 |
| Melanoma | 172._ | Bleomycin (Blenoxane) | |
| Alemtuzumab (Campath) | | Cervix | 180._ |
| Chronic Lymphocytic Leukemia | 204.1_ | Esophagus ¹ | 150._ |
| Alitretinoin (Panretin) | | Head & Neck | 140._ to 149._, 160._, 161._, 195.0 |
| Kaposi's Sarcoma (topical) | 176._ | Hodgkin's Lymphoma | 201._ _ |
| Altretamine (Hexalen) | | Kaposi's Sarcoma | 176._ |
| Lung ¹ (small cell) | 162._ | Malignant Peritoneal Effusion ¹ | 197.6 |
| Ovary ¹ | 183.0 | Malignant Pleural Effusion | 197.2 |
| Amifostine (Ethylol) | | Melanoma ¹ | 172._ |
| Bone marrow toxicity, cisplatin-and cyclophosphamide-induced (prophylaxis), advanced solid tumors (140.0 to 203.8, 283._ _ to 285.9, 995.2, V58.1, E933.1°) | | Non-Hodgkin's Lymphomas | 200._ _ , 202._ _ |
| Bone marrow toxicity, cisplatin-induced (prophylaxis), head and neck carcinoma (140.0_ to 149.0._, 160._ to 161._, 195.0, 995.2, V58.1, E933.1°) | | Osteosarcoma ¹ | 170._, 198.5 |
| Bone marrow toxicity, cyclophosphamide-induced (prophylaxis), malignant lymphoma (200._ to 202._, 283._ _ to 285.9, 995.2, V58.1, E933.1°) | | Ovary (germ cell) | 183.0, 183.9 |
| Bone marrow toxicity, carboplatin-induced (prophylaxis), non-small cell lung cancer (162.0 to 162.9, 283._ _ to 258.9, 995.2, V58.1, E933.1°) | | Penis | 187.1 to 187.4 |
| Bone marrow toxicity, carboplatin-induced (prophylaxis) plus radiation therapy, head and neck carcinoma (140._ to 149._, 160._ to 161._, 195.0, 995.2, V58.0, V58.1) | | Skin | 173._ |
| Myelodysplastic Syndromes ¹ | 238.7 | Soft-Tissue Sarcomas ¹ | 171._ |
| Nephrotoxicity, cisplatin-induced (prophylaxis), advanced ovarian carcinoma, melanoma, non-small cell lung carcinoma, advanced solid tumors of non-germ cell origin (162.2 to 162.9, 183._, 198.6, 172._, 583.9, 995.2, V58.1, E933.1°) | | Squamous Cell Carcinomas of Skin | 173._ |
| Neurotoxicity, cisplatin-induced (prophylaxis), neuropathy and ototoxicity (357.6, 388.5, 389.12, 995.2, V58.1, E933.1°) | | Testes | 186._ |
| Reduction in the incidence of mucositis in patients receiving radiation therapy or radiation combined with chemotherapy (101, 990, 995.2, V58.0, V58.1) ¹ | | Thyroid ¹ | 193 |
| Reduction in the incidence of xerostomia associated with post-operative radiation treatment of head and neck cancer, where the radiation port includes a substantial portion of the parotid glands (V58.0, 140._ to 149._, 160._ to 161._, 195.0, 527.7, 990) | | Vulva | 184.4 |
| (Please consult your coding manual.) | | Trophoblastic Neoplasms | 236.1 |
| Aminoglutethimide (Cytadren) | | Bortezomib (Velcade) | |
| ACTH-Producing Tumors | 194.0, 194.3, 198.89, 234.8, 227.3, 237.0, 162._, 164.0, 157._, 193 | Mantle Cell Lymphoma ¹ | 202.80 |
| Adrenal Cortex ¹ | 194.0 | Multiple Myeloma | 203.0_ |
| Breast ¹ | 174._, 175._ | Busulfan (Myleran) | |
| Prostate ¹ | 185 | Acute Nonlymphocytic Leukemia ¹ | 205.0_ |
| Anastrozole (Arimidex) | | Chronic Myelocytic Leukemia | 205.1_ |
| Breast | 174._, 175._ | Preparative therapy in treatment of malignancies with BMT | |
| Arsenic Trioxide (Trisenox) | | Capecitabine (Xeloda) | |
| Acute Promyelocytic Leukemia | 205.0_ | Breast | 174._, 175._ |
| Asparaginase (Elspar, Kidrolase) | | Colorectal | 153._, 154._ |
| Acute Lymphocytic Leukemia | 204.0_ | | |
| Acute Nonlymphocytic Leukemia ³ (Childhood acute myeloid Leukemia) | 205.0_ | | |
| Non-Hodgkin's Lymphomas | 200.0_, 200.1_ | | |
| Azacitidine (Vidaza) | | | |
| Myelodysplastic Syndromes | 238.7 | | |
| Bacillus Calmette-Guerin (TheraCys, Tice) | | | |
| Bladder | 188._ | | |

Generic Drug Index ■ ANTINEOPLASTICS, BIOLOGICS, ANTIEMETICS, AND SUPPORTIVE CARE DRUGS

| AGENT/Indication(s) | ICD-9 Code(s) |
|--|-------------------------------------|
| Carboplatin (Paraplatin, Paraplatin Solution) | |
| Bladder | 188._ |
| Brain | 191._ |
| Breast ¹ | 174._, 175._ |
| Carcinoma of unknown primary ¹ | 199.0, 199.1 |
| Cervix ³ | 180._ |
| Endometrium ¹ | 182.0 |
| Esophagus ¹ (also GE junction adenocarcinomas) ¹ | 150._ |
| Fallopian tube ¹ | 183.2 |
| Head & Neck | 140._ to 149._, 160._, 161._, 195.0 |
| Hodgkin's Lymphoma ¹ | 201._ _ |
| Lung | 162._ |
| Melanoma ¹ | 172._ |
| Neuroblastoma ³ xx | 160._, 194.0 |
| Non-Hodgkin's Lymphoma ¹ | 200._ _ , 202._ _ |
| Ovary | 183.0 |
| Peritoneal ¹ | 158.8, 158.9, 197.6 |
| Retinoblastoma | 190.5 |
| Testes | 186._ |
| Wilms' Tumor ³ | 189.0 |
| Carmustine (BICNU) | |
| Brain | 191._ |
| Colorectal | 153._, 154._ |
| Cutaneous T-Cell Lymphoma ³ | 201._, 202._, 202.8_ |
| Hodgkin's Lymphoma | 201._ _ |
| Melanoma | 172._ |
| Multiple Myeloma | 203.0_ |
| Non-Hodgkin's Lymphomas | 200._ _ , 202._ _ |
| Stomach ¹ | 151._ |
| Waldenström Macroglobulinemia ¹ | 273.3 |
| Carmustine, Implantation-Local (BCNU, Gliadel) | |
| Brain ¹ | 191._ |
| Cetuximab (Erbix) | |
| Colorectal | 153._, 154._ |
| Head & Neck ¹ | 140._ to 149._, 160._, 161._, 195.0 |
| Chlorambucil (Leukeran) | |
| Chronic Lymphocytic Leukemia | 204.1_ |
| Cutaneous T-Cell Lymphoma ¹ | 201._, 202._, 202.8_ |
| Hairy Cell Leukemia | 202.4_ |
| Hodgkin's Lymphoma | 201._ _ |
| Non-Hodgkin's Lymphoma | 200._ _ , 202._ _ |
| Ovary (germ and nongerm cell) | 183.0, 183.9 |
| Trophoblastic Neoplasms | 181, 236.1, 186.9 |
| Waldenström Macroglobulinemia ¹ | 273.3 |
| Chlorotrianisene | |
| Prostate | 185 |
| Chromic Phosphate P 32 (Phosphocol P32) | |
| Malignant Peritoneal Effusion ¹ | 197.6 |
| Malignant Pleural Effusion ¹ | 197.2 |
| Ovary ¹ | 183.0 |
| Prostate ¹ | 185 |
| Cisplatin (Platinol) | |
| Adrenal Cortex | 194.0 |
| Anal | 154.2, 154.3 |
| Bladder | 188._ |
| Brain ³ | 191._ |
| Breast | 174._, 175._ |
| Carcinoma of unknown primary | 199.0, 199.1 |
| Cervix | 180._ |
| Endometrium | 182.0 |
| Esophagus | 150._ |

| AGENT/Indication(s) | ICD-9 Code(s) |
|---|-------------------------------------|
| Fallopian tube ¹ | 183.2 |
| Head & Neck | 140._ to 149._, 160._, 161._, 195.0 |
| Hodgkin's Lymphoma | 201._ _ |
| Kaposi's Sarcoma ¹ | 176._ |
| Kidney ³ (Rhabdoid Tumors) | 155._ |
| Liver | 155._ |
| Lung | 162._ |
| Melanoma | 172._ |
| Mesothelioma ³ | 158._, 163._ |
| Neuroblastoma | 160._, 194.0 |
| Non-Hodgkin's Lymphomas | 200._, 202._ |
| Osteosarcoma | 170._, 198.5 |
| Ovary (germ and nongerm cell) | 183.0, 183.9 |
| Penis ³ xx | 187.1 to 187.4 |
| Peritoneal ¹ | 158.8, 158.9 |
| Prostate | 185 |
| Retinoblastoma ¹ | 190.5 |
| Skin ¹ | 173._ |
| Soft-Tissue Sarcomas | 171._ |
| Stomach | 151._ |
| Testes | 186._ |
| Thymoma | 164.0, 164.8 |
| Thyroid | 193 |
| Trophoblastic Neoplasms | 181, 236.1, 186.9 |
| Vulvar ¹ | 184.1, 184.2, 184.3, 184.4 |
| Wilms' Tumor ¹ | 189.0 |
| Cladribine, Chlorodeoxyadenosine (Leustatin) | |
| Chronic Lymphocytic Leukemia ¹ | 204.1_ |
| ★Cutaneous T-cell Lymphoma ³ | 202.1_, 202.2_, 202.8_ |
| Non-Hodgkin's Lymphomas (refractory, low grade) | 200._ _ , 202.0_ to 202.9_ |
| Hairy Cell Leukemia | 202.4_ |
| Waldenström Macroglobulinemia ¹ | 273.3 |
| Clofarabine[†] (Clolar) | |
| (Pediatric) Acute Lymphoblastic Leukemia | 204.0_ |
| Corticotropin | |
| Antiemetic (chemotherapy-induced) ¹ | 787.01, 787.03, 995.2 |
| Hypercalcemia (assoc. with malignancy) ¹ | 275.42 |
| Cyclophosphamide (Cytosan, Neosar) | |
| Acute Lymphocytic Leukemia | 204.0_ |
| Acute Nonlymphocytic Leukemia | 205.0_ |
| Bladder ¹ | 188._ |
| Brain | 191._ |
| Breast | 174._, 175._ |
| Cervix ¹ | 180._ |
| ★Choriocarcinoma ³ | |
| Chronic Lymphocytic Leukemia | 204.1_ |
| Chronic Myelocytic Leukemia | 205.1_ |
| Cryoglobulinemia ³ | 273.2 |
| Endometrium ¹ | 182.0 |
| Ewing's Sarcoma | 170._ |
| Head & Neck ³ | 140._ to 149._, 160._, 161._, 195.0 |
| Hodgkin's Lymphoma | 201._ _ |
| Kidney ¹ | 189.0, 189.1 |
| Lung | 162._ |
| Multiple Myeloma | 203.0_ |
| Neuroblastoma | 160._ , 194.0 |
| Non-Hodgkin's Lymphomas | 200._ _ , 202._ _ |

Generic Drug Index ■ ANTINEOPLASTICS, BIOLOGICS, ANTIEMETICS, AND SUPPORTIVE CARE DRUGS

| AGENT/Indication(s) | ICD-9 Code(s) | AGENT/Indication(s) | ICD-9 Code(s) |
|---|--|---|--|
| Cyclophosphamide (Cytoxan, Neosar) (cont'd) | | Daunorubicin, Liposomal (Daunoxome) | |
| Osteosarcoma ¹ | 170._, 198.5 | Kaposi's Sarcoma | 176._ |
| Ovary (germ and nongerm cell) | 183.0, 183.9 | Denileukin Diftitox (ONTAK) | |
| ★Pheochromocytoma ³ | | Cutaneous T-Cell Lymphoma | 202.1_, 202.2_, 202.8_ |
| Preparative therapy in treatment of malignancies with BMT | | Dexamethasone | |
| Prostate | 185 | Acute Lymphocytic Leukemia | 204.0_ |
| Retinoblastoma | 190.5 | Antiemetic (chemotherapy-induced) | 787.01, 787.03, 995.2 |
| Soft-Tissue Sarcomas | 171._ | Brain ¹ | 191._ |
| Thymoma ¹ | 164.0, 164.8 | Breast | 174._, 175._ |
| Testes | 186._ | Chronic Lymphocytic Leukemia | 204.1_ |
| Trophoblastic Neoplasms ¹ | 181, 236.1, 186.9 | Chronic Myelocytic Leukemia ³ | 205.1_ |
| Waldenström Macroglobulinemia ¹ | 273.3 | Hodgkin's Lymphoma | 201._ _ |
| Wilms' Tumor | 189.0 | Hypercalcemia (assoc. with malignancy) | 275.42 |
| Cytarabine (Cytosar-U) | | Multiple Myeloma ¹ | 203.0_ |
| Acute Lymphocytic Leukemia | 204.0_ | Non-Hodgkin's Lymphoma ³ | 200.__, 202._ _ |
| Acute Nonlymphocytic Leukemia | 205.0_ | Prostate ¹ | 185 |
| Chronic Myelocytic Leukemia | 205.1_ | Dexrazoxane Hydrochloride (Zinecard) | |
| Hodgkin's Lymphoma ¹ | 201._ _ | Breast, doxorubicin-induced cardiomyopathy prophylaxis in | 174._, 175._, 995.2 |
| Lymphomatous Meningitis ¹ | 198.4 | Diethylstilbestrol (DES) | |
| Myelodysplastic Syndromes ¹ | 238.7 | Breast | 174._, 175._ |
| Non-Hodgkin's Lymphoma | 200._, 202._ | Prostate | 185 |
| Cytarabine Liposome Injection (DepoCyt) | J9098 10 mg | Docetaxel (Taxotere) | |
| Lymphomatous Meningitis ¹ | 198.4 | Bladder ¹ | 188._ |
| Dacarbazine (DTIC-Dome) | | Breast | 174._, 175._ |
| Hodgkin's Lymphoma | 201._ _ | Esophagus ¹ | 150._ |
| Melanoma | 172._ | Head & Neck ¹ | 140._ to 149._, 160._, 161._, 195.0 |
| Neuroblastoma ³ | 160._, 194.0 | Lung | 162._ |
| Pancreas | 157._ | Ovary ¹ | 183.0 |
| Soft-Tissue Sarcomas | 171._ | Prostate | 185 |
| Dactinomycin (Cosmegen) | | Stomach ¹ | 151._ |
| Acute Lymphocytic Leukemia ³ | 204.0_ | Dolasetron Mesylate (Anzemet) | |
| Ewing's Sarcoma | 170._ | Antiemetic (Chemotherapy-induced) | 787.01, 787.03, 995.2 |
| Kaposi's Sarcoma ¹ | 176._ | Doxorubicin (Adriamycin, RUBEX) | |
| Osteosarcoma | 170._, 198.5 | Acute Lymphocytic Leukemia | 204.0_ |
| Ovary ³ xx | 183._ | Acute Nonlymphocytic Leukemia | 205.0_ |
| Soft-Tissue Sarcomas ³ | 171._ | Adrenal Cortex ¹ | 194.0 |
| Testes | 186._ | Bladder | 188._ |
| Trophoblastic Neoplasms | 181, 236.1, 186.9 | Breast | 174._, 175._ |
| Wilms' Tumor | 189.0 | Carcinoid Tumors ¹ | 152._, 153._, 155._ to 157._, 162.2 to 162.9, 183.0, 259.2 |
| Darbepoetin Alfa (Aranesp) | | Cervix | 180._ |
| Anemia of Malignancy ¹ | | Chronic Lymphocytic Leukemia ¹ | 204.1_ |
| Chronic Anemia (Chemotherapy-induced associated with malignancy) ¹ | 285.21, 285.22, 285.9, V58.11°, V66.2° | Endometrium | 182.0 |
| Chronic Illness (renal failure) | | Esophagus ¹ | 150._ |
| Daunorubicin (Cerubidine) | | Ewing's Sarcoma | 170._ |
| Acute Lymphocytic Leukemia | 204.0_ | Head & Neck | 140._ to 149._, 160._, 161._, 195.0 |
| Acute Nonlymphocytic Leukemia | 205.0_ | Hodgkin's Lymphoma | 201._ _ |
| Chronic Myelocytic Leukemia | 205.1_ | Kaposi's Sarcoma | 176._ |
| Chronic Myelomonocytic Leukemia | 205.10, 205.11 | Liver ¹ | 155._ |
| Ewing's Sarcoma ¹ | 170._ | | |
| Neuroblastoma ¹ | 160._, 194.0 | | |
| Non-Hodgkin's Lymphomas ¹ | 200.__, 202._ _ | | |
| Wilms' Tumor ¹ | 189.0 | | |

Generic Drug Index ■ ANTINEOPLASTICS, BIOLOGICS, ANTIEMETICS, AND SUPPORTIVE CARE DRUGS

| AGENT/Indication(s) | ICD-9 Code(s) |
|--------------------------------------|-------------------|
| Lung | 162._ |
| Multiple Myeloma | 203.0_ |
| Neuroblastoma | 160._, 194.0 |
| Non-Hodgkin's Lymphoma | 200.__, 202.__ |
| Osteosarcoma | 170._, 198.5 |
| Ovary (germ and nongerm cell) | 183.0, 183.9 |
| Pancreas ¹ | 157._ |
| Prostate | 185 |
| Retinoblastoma ¹ | 190.5 |
| Soft-Tissue Sarcomas | 171._ |
| Stomach | 151._ |
| Testes | 186._ |
| Thymoma ¹ | 164.0, 164.8 |
| Thyroid | 193 |
| Trophoblastic Neoplasms ¹ | 181, 236.1, 186.9 |
| Wilms' Tumor | 189.0 |

Doxorubicin, Liposomal (Doxil)

| | |
|-------------------------------|--------------|
| Breast ¹ | 174._, 175._ |
| Kaposi's Sarcoma | 176._ |
| Multiple Myeloma ¹ | 203.0_ |
| Ovary | 183.0 |

Epirubicin Hydrochloride (Ellence)

| | |
|-------------------------------------|----------------|
| Breast | 174._, 175._ |
| Esophagus ¹ | 150._ |
| Hodgkin's Lymphoma ¹ | 201.__ |
| Lung ¹ | 162._ |
| Non-Hodgkin's Lymphoma ¹ | 200.__, 202.__ |
| Ovary ¹ | 183.0 |
| Soft Tissue Sarcomas ¹ | 171._ |
| Stomach ¹ | 151._ |

Epoetin Alfa (Procrit, Epogen)

| | |
|--|---------|
| Anemia of Malignancy ¹ | |
| Chemotherapy | V58.11° |
| Chronic anemia (Chemotherapy-induced associated with malignancy) | 285.9 |
| Anemia associated with chronic illness (HIV, renal failure) | 285.2_ |
| Myelodysplastic Syndromes | 238.7 |
| Reduction of allogeneic blood transfusion in anemic surgery | |

Erlotinib Hydrochloride (Tarceva)

| | |
|----------------------|-------|
| Lung, non-small cell | 162._ |
| ★Pancreas | 157._ |

Estradiol

| | |
|----------|--------------|
| Breast | 174._, 175._ |
| Prostate | 185 |

Estradiol Valerate

| | |
|----------|--------------|
| Breast | 174._, 175._ |
| Prostate | 185 |

Estramustine (Emcyt)

| | |
|----------|-----|
| Prostate | 185 |
|----------|-----|

| AGENT/Indication(s) | ICD-9 Code(s) |
|---------------------|---------------|
|---------------------|---------------|

Estrogens (Conjugated & Esterified)

| | |
|----------|--------------|
| Breast | 174._, 175._ |
| Prostate | 185 |

Estrone

| | |
|----------|-----|
| Prostate | 185 |
|----------|-----|

Ethinyl Estradiol (Estinyl)

| | |
|----------|--------------|
| Breast | 174._, 175._ |
| Prostate | 185 |

Etidronate (Didronel)

| | |
|--|--------|
| Hypercalcemia (assoc. with malignancy) | 275.42 |
| Paget's Disease of Bone | 731.0 |

Etoposide (Toposar, VePesid)

| | |
|---|----------------------|
| Acute Lymphocytic Leukemia ¹ | 204.0_ |
| Acute Nonlymphocytic Leukemia | 205.0_ |
| Adrenal Cortex ¹ | 194.0 |
| Bladder | 188._ |
| Brain | 191._ |
| Carcinoma of unknown primary ¹ | 199._ |
| Cutaneous T-cell Lymphoma ¹ | 201._, 202._, 202.8_ |
| Endometrium ¹ | 182.0 |
| Ewing's Sarcoma | 170._ |
| Hodgkin's Lymphoma | 201.__ |
| Kaposi's Sarcoma | 176._ |
| Liver | 155.0, 155.2 |
| Lung | 162._ |
| Multiple Myeloma ¹ | 203.0_ |
| Neuroblastoma | 160._, 194.0 |
| Non-Hodgkin's Lymphoma | 200.__, 202.__ |
| Osteosarcoma | 170._, 198.5 |
| Ovary (germ and nongerm cell) | 183.0, 183.9 |
| Retinoblastoma ¹ | 190.5 |
| Soft Tissue Sarcomas | 171._ |
| Stomach ¹ | 151._ |
| Testes | 186._ |
| Thymoma ¹ | 164.0, 164.8 |
| Trophoblastic Neoplasms | 181, 236.1, 186.9 |
| Wilms' Tumor | 189.0 |

Etoposide Phosphate (Etopophos)

Same indications as Etoposide

Exemestane (Aromasin)

| | |
|--------|--------------|
| Breast | 174._, 175._ |
|--------|--------------|

Filgrastim (Neupogen)

| | |
|--|-------------------|
| Acute Myeloid Leukemia | 205._ to 208.01 |
| Chemotherapy | V66.2° or V58.11° |
| PBPC Mobilization | |
| Myelodysplastic Syndromes | 238.7 |
| Neutropenia (Chemotherapy-induced, assoc. with bone marrow transplant) | 288.0 |

Floxuridine (FUDR)

| | |
|---------------------|--------------|
| Colorectal | 153._, 154._ |
| Kidney ¹ | 189.0, 189.1 |
| Liver | 155._ |
| Ovary ¹ | 183.0 |

Generic Drug Index ■ ANTINEOPLASTICS, BIOLOGICS, ANTIEMETICS, AND SUPPORTIVE CARE DRUGS

| AGENT/Indication(s) | ICD-9 Code(s) |
|---|--|
| Fludarabine Phosphate (Fludara) | |
| Acute Nonlymphocytic Leukemia ³ xx | 205.0_ |
| Chronic Lymphocytic Leukemia | 204.1_ |
| Cutaneous T-Cell Lymphoma ³ | 202.1_, 202.2_ |
| Hairy Cell Leukemia ³ | 202.4_ |
| Non-Hodgkin's Lymphoma | 200._, 202.__ |
| Prolymphocytic Leukemia | 204.9_ |
| Waldenström Macroglobulinemia ³ | 273.3 |
| Fluorouracil (Acrucil, Efudex, Fluoroplex) | |
| Adrenal Cortex ¹ | 194.0 |
| Anal ¹ | 154.2, 154.3 |
| Bladder | 188._ |
| Breast | 174._, 175._ |
| Carcinoid Tumors ¹ | 152._, 153._, 155._ to 157._, 162.2 to 162.9, 183.0, 259.2 |
| Cervix | 180._ |
| Colorectal | 153._, 154._ |
| Endometrium ¹ | 182.0 |
| Esophagus | 150._ |
| Head & Neck | 140._ to 149._, 160._, 161._, 195.0 |
| Kidney ³ xx | 189.0, 189.1 |
| Liver | 155._ |
| Lung | 162._ |
| Ovary | 183.0 |
| Pancreas | 157._ |
| Penis ¹ | 187.1 to 187.4, 187.8 |
| Prostate ¹ | 185 |
| Skin (topical 5-FU) | 173._ |
| Stomach | 151._ |
| Vulvar ¹ | 184.1, 184.2, 184.3, 184.4 |
| Fluoxymesterone (Halotestin) | |
| Breast | 174._, 175._ |
| Flutamide (Eulexin) | |
| Prostate | 185 |
| Fulvestrant (Faslodex) | |
| Breast | 174._, 175._ xx |
| Gallium Nitrate (Ganite) | |
| Hypercalcemia | 275.42 |
| Gefitinib (Iressa) | |
| Lung | 162._ |
| Gemcitabine Hydrochloride (Gemzar) | |
| Bladder | 188._ |
| Breast | 174._, 175._ |
| Gallbladder (and biliary tract) ¹ | 156._ |
| Germ Cell Tumor ¹ | 183.0, 186._, 164.2, 164.3, 164.8, 164.9, 158._, 181, 194.4 |
| Hodgkin's Lymphoma ¹ | 201.__ |
| Lung (non-small cell) | 162._ |
| Non-Hodgkin's Lymphoma ¹ | 200._, 202._ |
| Ovary | 183.0 |
| Pancreas | 157._ |
| Testes ¹ | 186._ |

| AGENT/Indication(s) | ICD-9 Code(s) |
|--|--|
| Gemtuzumab Ozogamicin (Mylotarg) | |
| Acute Myeloid Leukemia | 205.__ |
| Goserelin (Zoladex) | |
| Breast | 174._, 175._ |
| Endometrium | 182.0 |
| Prostate | 185 |
| Granisetron Hydrochloride (Kytril) | |
| Antiemetic (Chemotherapy-induced) (Associated with radiation ¹) | 787.01, 787.03, 995.2 |
| Hydrocortisone | |
| Antiemetic (chemotherapy-induced) | 787.01, 787.03, 995.2 |
| Hypercalcemia (assoc. with malignancy) | 275.42 |
| Hydroxyprogesterone (Prodox) | |
| Endometrium ³ | 182.0 |
| Uterus | 182._ |
| Hydroxyurea (Hydrea) | |
| Cervix | 180._ |
| Chronic Myelocytic Leukemia | 205.1_ |
| Head & Neck | 140._ to 149._, 160._, 161._, 195.0 |
| Melanoma | 172._ |
| Ovary | 183.0 |
| Polycythemia Vera | 238.4 |
| Thrombocytosis | 289.9 |
| Ibritumomab Tiuxetan (Zevalin) | |
| Non-Hodgkin's Lymphoma | 200.__, 202.__ |
| Idarubicin (Idamycin) | |
| Acute Lymphocytic Leukemia ¹ | 204.0_ |
| Acute Nonlymphocytic Leukemia | 205.0_ |
| Ifosfamide (Ifex) | |
| Acute Lymphocytic Leukemia | 204.0_ |
| Bladder | 188._ |
| Breast ¹ | 174._, 175._ |
| Cervix | 180._ |
| Endometrium ¹ | 182.0 |
| Ewing's Sarcoma | 170._ |
| Head & Neck ¹ | 140._ to 149._, 160._, 161._, 195.0 |
| Hodgkin's Lymphomas ¹ | 201.__ |
| Lung | 162._ |
| Neuroblastoma ¹ | 160._, 194.0 |
| Non-Hodgkin's Lymphoma | 200._, 202._ |
| Osteosarcoma | 170._, 198.5 |
| Ovary (germ and nongerm cells) | 183._, 183.9 |
| Pancreas ¹ | 157._ |
| Soft Tissue Sarcomas | 171._ |
| Testes (germ cell) | 186._ |
| Thymoma ¹ | 164.0, 164.8 |
| Uterus ³ xx | 182._ |
| Wilms' Tumor | 189.0 |

Generic Drug Index ■ ANTINEOPLASTICS, BIOLOGICS, ANTIEMETICS, AND SUPPORTIVE CARE DRUGS

| AGENT/Indication(s) | ICD-9 Code(s) | AGENT/Indication(s) | ICD-9 Code(s) |
|---|------------------------|--|-------------------------------------|
| Imatinib Mesylate (Gleevec) | | Leucovorin (Leucovorin Calcium, Wellcovorin) | |
| Chronic Myelogenous Leukemia | 205.1_ | Colorectal | 153._, 154._ |
| Gastrointestinal Stromal Tumors | 171.8 | Ewing's Sarcoma ¹ | 170._ |
| | | Head & Neck ¹ | 140._ to 149.0, 160._, 161._, 195.0 |
| Immune Globulin IGIV | | Non-Hodgkin's Lymphoma ¹ | 200._, 202._ |
| Bacterial infections (associated with B-Cell chronic lymphocytic leukemia) | 790.7 | Osteosarcoma | 170._, 198.5 |
| | | Trophoblastic Neoplasmas ¹ | 181, 236.1, 186.9 |
| Interferon Alpha-2a (Roferon A) | | Leuprolide (Lupron, Lupron Depot) | |
| Bladder | 188._ | Breast | 174._ |
| Brain | 191._ | Endometrium (endometriosis, endometriotic lesions, only) | 617._ |
| Carcinoid Syndrome | 259.2 | Prostate | 185 |
| Chronic Lymphocytic Leukemia ³ | 204.1_ | | |
| Chronic Myelocytic Leukemia | 205.1_ | Levamisole (Ergamisol) | |
| Cutaneous T-Cell Lymphoma | 202.1_, 202.2_, 202.8_ | Colorectal | 153._, 154._ |
| Esophagus ¹ | 150._ | | |
| Hairy Cell Leukemia | 202.4 | Levodopa | |
| Kaposi's Sarcoma | 176._ | Bone Lesions ³ | 170._, 198.5 |
| Kidney | 189.0, 189.1 | | |
| Melanoma | 172._ | Levothyroxine | |
| Multiple Myeloma | 203.0_ | Thyroid | 193 |
| Non-Hodgkin's Lymphomas | 200.__, 202.__ | | |
| Ovary | 183.0 | Liothyronine | |
| Polycythemia Vera ¹ | 238.4 | Thyroid | 193 |
| Skin | 173._ | | |
| | | Liotrix | |
| Interferon Alpha-2b (Intron A, Rebetrone) | | Thyroid | 193 |
| Bladder | 188._ | | |
| Brain | 191._ | Lomustine (CeeNU) | |
| Carcinoid Syndrome | 259.2 | Brain | 191._ |
| Chronic Lymphocytic Leukemia ³ | 204.1_ | Breast | 174._, 175._ |
| Chronic Myelocytic Leukemia | 205.1_ | Colorectal | 153._, 154._ |
| Condyloma Acuminatum | 078.11 | Hodgkin's Lymphoma | 201.__ |
| Cutaneous T-Cell Lymphoma | 202.1_, 202.2_, 202.8_ | Lung | 162._ |
| Hairy Cell Leukemia | 202.4 | Melanoma ¹ | 172._ |
| Kaposi's Sarcoma | 176._ | Multiple Myeloma ¹ | 203.00 to 203.01 |
| Kidney | 189.0, 189.1 | | |
| Melanoma | 172._ | Masoprocol (Actinex) | |
| Multiple Myeloma | 203.0_ | Skin (topical) ¹ | 173._ |
| Non-Hodgkin's Lymphomas | 200.__, 202.__ | | |
| Ovary | 183._ | Mechlorethamine (Mustargen) | |
| Polycythemia Vera ¹ | 238.4 | Chronic Myelocytic Leukemia | 205.1_ |
| Skin | 173._ | Cutaneous T-cell Lymphoma ¹ | 202.1_, 202.2_, 202.8_ |
| | | Hodgkin's Lymphoma | 201.__ |
| Irinotecan Hydrochloride (Camptosar) | J9206 20 mg | Lung | 162._ |
| Cervix ³ xx | 180._ | Malignant Pericardial Effusion | 164.1 |
| Colorectal | 153._, 154._ | Malignant Peritoneal Effusion | 197.6 |
| Lung (small-cell) ³ | 162._ | Malignant Pleural Effusion | 197.2 |
| Lung (non small-cell) ¹ | 162._ | Non-Hodgkin's Lymphoma | 200.__, 202.__ |
| | | | |
| Ketoconazole (Nizoral) | | Medroxyprogesterone (Provera, Depo-Provera) | |
| Adrenal Cortex ³ | 194.0 | Breast | 174._ |
| Prostate | 185 | Endometrial | 182.0 |
| | | Kidney | 189.0, 189.1 |
| ★Lenalidomide[†] (Revlimid) | 238.7 | | |
| Transfusion-dependent anemia due to low- or intermediate-risk myelodysplastic syndromes | | Megestrol (Megace) | |
| | | Breast | 174._, 175._ |
| Letrozole (Femara) | | Cachexia | 199.1, 799.4 |
| Breast | 174._ | Endometrial | 182.0 |

Generic Drug Index ■ ANTINEOPLASTICS, BIOLOGICS, ANTIEMETICS, AND SUPPORTIVE CARE DRUGS

| AGENT/Indication(s) | ICD-9 Code(s) | AGENT/Indication(s) | ICD-9 Code(s) |
|--|-------------------------------------|--|-------------------------------------|
| Melphalan (Alkeran) | | | |
| Breast | 174._ | Chronic Myelocytic Leukemia ¹ | 205.1_ |
| Chronic Myelocytic Leukemia | 205.1_ | Colorectal | 153._, 154._ |
| Endometrial ¹ | 182.0 | Esophagus ¹ | 150._ |
| Hodgkin's Lymphoma ¹ | 201._ _ | Gallbladder ¹ | 156.0 |
| Melanoma | 172._ | Head & Neck | 140._ to 149._, 160._, 161._, 195.0 |
| Multiple Myeloma | 203.0_ | Lung | 162._ |
| Osteosarcoma ³ | 170._, 198.5 | Pancreas | 157._ |
| Ovary | 183.0 | Stomach | 151._ |
| Prostate ³ | 185 | Mitotane (Lysodren) | |
| Soft Tissue Sarcomas ³ | 171._ | Adrenal Cortex | 194.0 |
| Testes ³ | 186._ | Mitoxantrone (Novantrone) | |
| Waldenström Macroglobulinemia ¹ | 273.3 | Acute Lymphocytic Leukemia ¹ | 204.0_ |
| Mercaptopurine (Purinethol, 6-MP) | | Acute Nonlymphocytic Leukemia | 205.0_ |
| Acute Lymphocytic Leukemia | 204.0_ | Breast ¹ | 174._, 175._ |
| Acute Nonlymphocytic Leukemia | 205.0_ | Liver ¹ | 155._ |
| Chronic Myelocytic Leukemia | 205.1_ | Non-Hodgkin's Lymphomas | 200._ _ , 202._ _ |
| Hodgkin's Lymphoma ³ | 201._ _ | Prostate | 185 |
| Non-Hodgkin's Lymphoma | 200._ _ to 202._ _ | Nandrolone | |
| Mesna (Mesnex) | | Breast ¹ | 174._, 175._ |
| Hemorrhagic Cystitis | 595.82, 995.2 | ★Nelarabine (Arranon)[†] | |
| (Cyclophosphamide-/Ifosfamide-induced) | | Acute Lymphoblastic Leukemia, T-cell | |
| Methotrexate (Folex, Mexate) | | Lymphoblastic Lymphoma, T-cell | |
| Acute Lymphocytic Leukemia | 204.0_ | Nilutamide | |
| Acute Nonlymphocytic Leukemia | 205.0_ | Prostate | 185._ |
| Bladder | 188._ | Octreotide (Sandostatin, Sandostatin LAR Depot) | |
| Brain ¹ | 191._ | Carcinoid Tumors | 259.2 |
| Breast | 174._, 175._ | Pancreas | 157._ |
| Carcinomatous Meningitis | 198.4 | Chemotherapy-induced diarrhea ¹ | 787.91 |
| Cervix ¹ | 180._ | Ondansetron Hydrochloride (Zofran) | |
| Colorectal ¹ | 153._, 154._ | Antiemetic (chemotherapy-induced) | 787.01, 787.03, 995.2 |
| Esophagus ¹ | 150._ | Oprelvekin (Neumega) | |
| Head & Neck | 140._ to 149._, 160._, 161._, 195.0 | Non-myeloid Malignancy ¹ | 140._ to 202._ |
| Hodgkin's Lymphoma ¹ | 201._ _ | Secondary Thrombocytopenia, due to drug therapy ¹ | 287.4 |
| Lung | 162._ | Oxaliplatin (Eloxatin) | |
| Non-Hodgkin's Lymphomas | 200._ _ , 202._ _ | Colorectal | 153._, 154._ |
| Osteosarcoma | 170._, 198.5 | Oxandrolone (Oxandrin) | |
| Ovary ¹ | 183.0 | Involuntary weight loss | 783.21 |
| Pancreas ¹ | 157._ | Paclitaxel (Taxol, Onxol) | |
| Penis ¹ | 187.1 to 187.4, 187.8 | Bladder | 188._ |
| Soft Tissue Sarcoma ¹ | 171._ | Breast | 174._, 175._ |
| Stomach ¹ | 151._ | Carcinoma of unknown primary ¹ | 199.0, 199.1 |
| Trophoblastic Neoplasms | 181, 236.1, 186.9 | Cervix | 180._ |
| Methoxsalen (8-MOP) | | Endometrial ¹ | 182.0 |
| Cutaneous T-Cell Lymphoma | 202.1_, 202.2_, 202.8_ | Esophagus | 150._ |
| Methyltestosterone | | | |
| Breast | 174._ | | |
| Mitomycin (Mutamycin) | | | |
| Anal | 154.2, 154.3 | | |
| Bladder | 188._ | | |
| Breast | 174._, 175._ | | |
| Cervix | 180._ | | |

Generic Drug Index ■ ANTINEOPLASTICS, BIOLOGICS, ANTIEMETICS, AND SUPPORTIVE CARE DRUGS

| AGENT/Indication(s) | ICD-9 Code(s) |
|--|-------------------------------------|
| Paclitaxel (Taxol, Onxol) (cont'd) | |
| Fallopian tube ¹ | 183.2 |
| Head & Neck | 140._ to 149._, 160._, 161._, 195.0 |
| Lung (Non-small cell and small cell) | 162._ |
| Kaposi's Sarcoma | 176._ |
| Ovary | 183.0 |
| Peritoneal ¹ | 158.8, 158.9 |
| Prostate ¹ | 185 |
| Stomach ¹ | 151._ |
| Testes ¹ | 186._ |
| Palifermin (Kepivance) | |
| Oral mucositis | |
| Palonosetron Hydrochloride (Aloxi) | |
| Antiemetic (Chemotherapy-induced) | 787.01, 787.03, 995.2 |
| Pamidronate Disodium (Aredia) | |
| Hypercalcemia (assoc. with malignancy) | 275.42 |
| Multiple Myeloma with bone metastases | 203.0_ and 198.5 |
| Osteolytic Bone Metastases (with breast cancer/myeloma) | 174._, 175._, 198.5 |
| Paget's Disease of Bone | 731.0 |
| Pegaspargase (Oncaspar) | |
| Acute Lymphocytic Leukemia | 204.0_ |
| Pegfilgrastim (Neulasta) | 288.0 |
| Infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs. | |
| Pemetrexed (Alimta) | |
| Lung (non-small cell) | 162._ |
| Mesothelioma | 163._ |
| Pentostatin (Nipent) | |
| Acute Lymphocytic Leukemia ³ | 204.0_ |
| Chronic Lymphocytic Leukemia ³ | 204.1_ |
| Cutaneous T-Cell Lymphoma ¹ | 202.1_, 202.2_, 202.8_ |
| Hairy Cell Leukemia | 202.4_ |
| Prolymphocytic Leukemia | 204.9_ |
| Plicamycin (Mithracin) | |
| Hypercalcemia (assoc. with malignancy) | 275.42 |
| Hypercalciuria (assoc. with malignancy) | 275.40 |
| Paget's Disease of Bone ¹ | 731.0 |
| Testes | 186._ |
| Porfimer Sodium (Photofrin) | |
| Esophagus ¹ | 150._ |
| Lung ¹ | 162._ |
| Prednisone (Deltasone) | |
| Acute Lymphocytic Leukemia | 204.0_ |
| Antiemetic (chemotherapy-induced) | 787.01, 787.03, 995.2 |
| Breast | 174._, 175._ |
| Chronic Lymphocytic Leukemia | 204.1_ |
| Chronic Myelocytic Leukemia ³ | 205.1_ |
| Hodgkin's Lymphoma | 201._ _ |
| Hypercalcemia (assoc. with malignancy) | 275.42 |

| AGENT/Indication(s) | ICD-9 Code(s) |
|---|--|
| Multiple Myeloma ¹ | 203.0_ |
| Non-Hodgkin's Lymphomas | 200._ _ , 202._ _ |
| Prostate ¹ | 185 |
| Waldenström Macroglobulinemia ¹ | 273.3 |
| Procarbazine (Matulane, Natulan) | |
| Brain | 191._ |
| Hodgkin's Lymphoma | 201._ _ |
| Lung | 162._ |
| Multiple Myeloma ¹ | 203.00 to 203.01 |
| Non-Hodgkin's Lymphomas | 200._ _ , 202._ _ |
| Raltitrexed (Tomudex) | |
| Colorectal ¹ (Available in Canada) | 153._, 154._ |
| Rituximab (Rituxan) | |
| Chronic Lymphocytic Leukemia ¹ | 204.1_ |
| Immune or Idiopathic Thrombocytopenic Purpura ¹ | 287.3 |
| Non-Hodgkin's Lymphomas | 200._ _ , 202._ _ |
| Waldenström Macroglobulinemia ¹ (also Reinduction Treatment of Indolent Non-Hodgkin's Lymphomas) ¹ | 273.3 |
| Sargramostim (Leukine) | |
| Chemotherapy | V58.1°, V66.2° |
| Neutropenia (assoc. with bone marrow transplant, chemotherapy-induced, including chemotherapy assoc. with acute myelogenous leukemia) | 288.0 |
| Myelodysplastic Syndromes | 238.7 |
| Sodium Iodide I 131 (Idotope) | |
| Thyroid ¹ | 193 |
| Sodium Phosphate P 32 | |
| Bone Lesions ¹ | 170._, 198.5 |
| Chronic Lymphocytic Leukemia ¹ | 204.1_ |
| Chronic Myelocytic Leukemia ¹ | 205.1_ |
| ★Sorafenib Tosylate (Nexavar)¹ | |
| Kidney | 189.0, 189.1 |
| Streptozocin (Zanosar) | |
| Carcinoid Tumors | 152._, 153._, 154.0, 154.1, 162.2 to 162.9, 183.0, 259.2 |
| Colorectal ¹ | 153._, 154._ |
| Pancreas | 157._ |
| ★Sunitinib (Sutent)[†] | |
| Gastrointestinal Stromal Tumors | 171.8 |
| Kidney | 189.0, 189.1 |
| Tamoxifen (Nolvadex) | |
| Breast | 174._ |
| Endometrium ¹ | 182.0 |
| Melanoma ¹ | 172._ |
| Temozolomide (Temodar) | |
| Brain (refractory anaplastic astrocytoma, glioblastoma multiforme ¹) | 191._ |
| Melanoma ¹ | 172._ |

AGENT/Indication(s)

ICD-9 Code(s)

PUBLICATION KEY

Unless otherwise noted, drugs/indications are recognized in both compendia.

1 = *USP DI*

The United States Pharmacopeial Convention, Inc.
12601 Twinbrook Parkway
Rockville, MD 20852
301/881-0666

3 = *AHFS Drug Information*

American Society of Health System Pharmacists, Inc.
7272 Wisconsin Ave.
Bethesda, MD 20814
301/657-3000

★ = Item has been added or changed since last issue.

o = Medicare may reimburse with this code.

xx = Check with your local Medicare carrier before submitting a claim for this indication.

† = New, FDA approved indication, not yet in compendia.

Why Orphan Drugs and Their Indications Are No Longer Included in This Publication

The Association of Community Cancer Centers' *Compendia-Based Drug Bulletin (ACCC Drug Bulletin)* is a quarterly update of information on oncology drugs recognized by the two national references: 1) the *USP DI Oncology*, a copyrighted publication of Micromedex, Inc., and 2) *AHFS Drug Information*, published by the American Society of Health-System Pharmacists. Medicare covers off-label uses of anticancer therapeutics regimens if they are supported by citation in at least one of these two compendia. A third compendium, the American Medical Association's *Drug Evaluation*, is no longer published, having been merged into the USP DI in 1996.

ACCC spearheaded efforts to make citation of a cancer drug in any of the standard reference compendia sufficient to require insurers to pay for its use outside of Food and Drug Administration (FDA) labeled indications. To date, 39 states have passed ACCC's off-label legislation with similar language to the Medicare rules.

Because of its wide circulation, frequent updates and on-line availability, many clinicians rely on the *ACCC Drug Bulletin* as a comprehensive source of information on oncology drug indications that have been either 1) approved by the FDA, or 2) recognized by one of the national compendia as clinically appropriate for off-label use.

The term "orphan drug" refers to either a drug or biologic under development for use in a rare disease or condition. A drug or biologic receives orphan-drug designation from the Office of Orphan Products Development at the FDA. Orphan-drug designation qualifies the sponsor to receive certain tax and other benefits from the government in exchange for developing the drug for a rare disease or condition. Orphan-drug designation, however, is independent of the FDA's process of approval for safety and efficacy.

Since clinicians, including insurer medical and pharmacy directors, are increasingly relying on the *ACCC Drug Bulletin* as an updated and comprehensive reference for established efficacy and safety, this and future editions will limit content to sources with this specific focus and intent.

AGENT/Indication(s)

ICD-9 Code(s)

Teniposide (Vumon)

| | |
|--------------------------------------|----------------|
| Acute Lymphocytic Leukemia | 204.0_ |
| Neuroblastoma ¹ | 160._, 194.0 |
| Non-Hodgkin's Lymphomas ¹ | 200.__, 202.__ |

Testolactone (Teslac)

| | |
|--------|--------------|
| Breast | 174._, 175._ |
|--------|--------------|

Testosterone

| | |
|--------|--------------|
| Breast | 174._, 175._ |
|--------|--------------|

Thalidomide (Thalomid)

| | |
|----------------------------------|--------------|
| Brain ³ xx | 191._ |
| Breast ³ xx | 174._, 175._ |
| Cachexia ³ xx | 199.1, 799.4 |
| Kaposi's Sarcoma ³ xx | 176._ |
| Kidney ³ xx | 189.0, 189.1 |
| Melanoma ³ xx | 172._ |
| Multiple Myeloma | 203.0_ |
| Ovary ³ xx | 183.0 |
| Prostate ³ xx | 185 |

Thioguanine

| | |
|-------------------------------|------------------|
| Acute Lymphocytic Leukemia | 204.00, 204.01 |
| Acute Nonlymphocytic Leukemia | 205.00 to 205.01 |
| Chronic Myelocytic Leukemia | 205.10, 205.11 |

Thiotepa

| | |
|---------------------------------------|--------------|
| Bladder | 188._ |
| Breast | 174._, 175._ |
| Carcinomatous Meningitis ¹ | 198.4 |
| Hodgkin's Lymphoma ¹ | 201.__ |
| Malignant Pericardial Effusion | 164.1 |
| Malignant Peritoneal Effusion | 197.6 |
| Malignant Pleural Effusion | 197.2 |
| Ovary | 183.0 |

Thyroglobulin

| | |
|---------|-----|
| Thyroid | 193 |
|---------|-----|

Thyroid

| | |
|---------|-----|
| Thyroid | 193 |
|---------|-----|

Thyrotropin

| | |
|---------|-----|
| Thyroid | 193 |
|---------|-----|

Topotecan Hydrochloride (Hycamtin) J9350 4 mg

| | |
|--|--------|
| Chronic Myelomonocytic Leukemia ¹ | 205.1_ |
| Lung (small and non-small cell) | 162._ |
| Myelodysplastic Syndromes ¹ | 238.7 |
| Ovary | 183.0 |

Toremifene Citrate (Fareston)

| | |
|--------|-------|
| Breast | 174._ |
|--------|-------|

Tositumomab, Iodine I-131 (Bexxar)

| | |
|-------------------------|----------------|
| Non-Hodgkin's Lymphomas | 200.__, 202.__ |
|-------------------------|----------------|

Trastuzumab (Herceptin)

| | |
|--------|--------------|
| Breast | 174._, 175._ |
|--------|--------------|

Treosulfan (Ovastat)

| | |
|--------------------|-------|
| Ovary ¹ | 183.0 |
|--------------------|-------|

Generic Drug Index ■ ANTINEOPLASTICS, BIOLOGICS, ANTIEMETICS, AND SUPPORTIVE CARE DRUGS

| INDICATION/Agent(s) | ICD-9 Code(s) | INDICATION/Agent(s) | ICD-9 Code(s) |
|--|---|---|--|
| Tretinoin (Vesanoid) | | Kidney | 189.0, 189.1 |
| Acute Promyelocytic Leukemia ¹ | 205.0_ | Liver ¹ | 155.0, 155.2 |
| Trilostane | | Lung | 162._ |
| ACTH-Producing Tumors | 194.3, 198.89, 234.8, 227.3, 237.0, 162._, 164.0, 157._, 193 | Melanoma ¹ | 172._ |
| Adrenal Cortex ¹ | 194.0 | Multiple Myeloma | 203.0_ |
| Trimetrexate | | Neuroblastoma | 160._, 194.0 |
| Colorectal ¹ | 153._, 154._ | Non-Hodgkin's Lymphoma | 200.__, 202.__ |
| Triptorelin Pamoate (Trelstar Depot) | | Osteosarcoma | 170._, 198.5 |
| Prostrate ³ | 185 | Ovary ¹ (germ cell) | 183.0 |
| Troxacitabine (Troxatyl) | | Retinoblastoma ¹ | 190.5 |
| Acute Myeloid Leukemia★★★ | 205.__ | Rhabdomyosarcoma | 171._, 143.9, 158.0, 190.1, 173.9, 174.9, 175.9 |
| Uracil Mustard | | Soft Tissue Sarcomas | 171._ |
| Cervix ³ | 180.0 | Trophoblastic Neoplasms ¹ | 181, 236.1, 186.9 |
| Chronic Lymphocytic Leukemia | 204.1_ | Waldenström Macroglobulinemia ¹ | 273.3 |
| Chronic Myelocytic Leukemia | 205.1_ | Wilms' Tumor | 189.0 |
| Hodgkin's Lymphoma ³ | 201.__ | Vinorelbine Tartrate (Navelbine) | |
| Lung ³ | 162._ | Breast | 174._, 175._ |
| Non-Hodgkin's Lymphoma | 200.__, 202.__ | Cervix | 180._ |
| Ovary ³ | 183.0 | Lung (non-small cell) | 162._ |
| Valrubicin (Valstar) | | Ovary ¹ | 183.0 |
| Bladder | 188._, 233.7 | Zoledronic Acid (Zometa) | |
| Vinblastine (Velban) | | Hypercalcemia (assoc. with malignancy) | 275.42 |
| Bladder | 188._ | Multiple Myeloma | 203.0_ |
| Breast | 174._, 175._ | Bone Metastases from solid tumors, sometimes found with breast carcinoma, multiple myeloma, non-small cell lung carcinoma, renal cell carcinoma, head and neck carcinoma, and prostate carcinoma. ¹ | 198.5 |
| Cutaneous T-Cell Lymphoma | 202.1_, 202.2_, 202.8_ | Drug-induced osteopenia, secondary to androgen-deprivation therapy in prostate cancer patients (prophylaxis) ¹ | 733.90 |
| Head & Neck | 140._ to 149._, 161._, 195.0 | | |
| Hodgkin's Lymphoma | 201.__ | | |
| Immune or Idiopathic Thrombocytopenic Purpura ³ | 287.3 | | |
| Kaposi's Sarcoma | 176._ | | |
| Kidney | 189.0, 189.1 | | |
| Lung | 162._ | | |
| Melanoma | 172._ | | |
| Neuroblastoma ¹ | 160._, 194.0 | | |
| Non-Hodgkin's Lymphomas | 200.__, 202.__ | | |
| Ovary ¹ (germ cell) | 183.0 | | |
| Prostate ¹ | 185._ | | |
| Testes | 186._ | | |
| Trophoblastic Neoplasms | 181, 236.1, 186.9 | | |
| Vincristine (Oncovin, Vincasar) | | | |
| Acute Lymphocytic Leukemia | 204.0_ | | |
| Acute Nonlymphocytic Leukemia ³ ×× | 205.0_ | | |
| Brain | 191._ | | |
| Breast | 174._, 175._ | | |
| Cervix ¹ | 180._ | | |
| Chronic Lymphocytic Leukemia | 204.1_ | | |
| Chronic Myelocytic Leukemia ¹ | 205.1_ | | |
| Colorectal ¹ | 153._, 154._ | | |
| Cutaneous T-Cell Lymphoma ¹ | 202.1_, 202.2_, 202.8_ | | |
| Ewing's Sarcoma | 170._ | | |
| Hodgkin's Lymphoma | 201.__ | | |
| Kaposi's Sarcoma | 176._ | | |
| Immune or Idiopathic Thrombocytopenic Purpura ³ | 287.3 | | |

Indication Index

| INDICATION/Agent(s) | ICD-9 Code(s) |
|---|-------------------------------|
| ACTH-Producing Tumors | 194.3, 198.89, 234.8, 227.3, |
| Aminoglutethimide, Trilostane ¹ | 237.0, 162., 164.0, 157., 193 |
| Acute Lymphocytic Leukemia | 204.0_ |
| Asparaginase, Clofarabine [†] (Pediatric), Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Etoposide, Idarubicin, ¹ Ifosfamide, Mercaptopurine, Methotrexate, Mitoxantrone, ¹ ★Nelarabine, [†] Pegaspargase, Pentostatin ³ , Prednisone, Teniposide, Thioguanine, Vincristine | |
| Acute Nonlymphocytic Leukemia (Erythroleukemia, Meningeal, Monocytic, Myelocytic, Myelomonocytic, Promyelocytic) | 205.0_ |
| Aldesleukin ³ XX, Asparaginase, ³ Busulfan, ¹ Cyclophosphamide, Cytarabine, Daunorubicin, Doxorubicin, Etoposide, Fludarabine Phosphate ³ XX, Gemtuzumab, Idarubicin, Mercaptopurine, Methotrexate, Mitoxantrone, Thioguanine, Tretinoin, ¹ Vincristine ³ XX | |
| Adrenal Cortex | 194.0 |
| Aminoglutethimide, ¹ Cisplatin, Doxorubicin, ¹ Etoposide, ¹ Fluorouracil ¹ , Ketoconazole, ³ Mitotane, Trilostane ¹ | |
| Antiemetic | 787.01, 787.03, 995.2, V58.1° |
| Corticotropin, ¹ Dexamethasone, ¹ Dolasetron Mesylate, Granisetron Hydrochloride, Hydrocortisone, ¹ Ondansetron Hydrochloride, Palonosetron Hydrochloride, Prednisone | |
| Bacterial Infections (assoc. with B-cell chronic lymphocytic leukemia) | 790.7 |
| Immune Globulin IGIV | |
| Bladder | 188._ |
| Bleomycin, Carboplatin, Cisplatin Cyclophosphamide, ¹ Docetaxel, ¹ Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Ifosfamide, Interferon Alpha 2a & 2b, Methotrexate, Mitomycin, Paclitaxel, Thiotepa, Valrubicin (233.7), Vinblastine | |
| Bone Lesions | 170., 198.5 |
| Levodopa, ³ Sodium Phosphate P 32 ¹ , Zoledronic Acid ¹ | |
| Brain | 191._ |
| Carboplatin, Carmustine, Cisplatin, ³ Cyclophosphamide, Dexamethasone, ¹ Etoposide, Interferon Alpha 2a, Interferon Alpha-2b, Lomustine, Methotrexate, ¹ Procarbazine, Temozolomide, Thalidomide, ³ XX Vincristine | |
| Breast | 174., 175._ |
| Abraxane, Aminoglutethimide, ¹ Anastrozole, Capecitabine, Carboplatin, ¹ Cisplatin, Cyclophosphamide, Dexamethasone, Dexrazoxane, Docetaxel, Doxorubicin, Doxorubicin, Liposomal, ¹ Epirubicin Hydrochloride, Estradiol, Estradiol Valerate, Estrogens (Conjugated & Esterified), Ethinyl, Exemestane, Fluorouracil, Fluoxymesterone, Fulvestrant, Gemcitabine, Goserelin, Ifosfamide, ¹ Letrozole, Leuprolide, Lomustine, Medroxyprogesterone, Megestrol, Melphalan, Methotrexate, Methyltestosterone, Mitomycin, Mitoxantrone, ¹ Nandrolone, ¹ Pamidronate Disodium, ¹ Paclitaxel, Prednisone, Tamoxifen, Testolactone, Testosterone, Thalidomide ³ XX, Thiotepa, Toremifene, Trastuzumab, Vinblastine, Vincristine, Vinorelbine Tartrate | |

| INDICATION/Agent(s) | ICD-9 Code(s) |
|---|--|
| Cachexia | 199.1, 799.4 |
| Megace, Thalidomide ³ XX Oxandrin (involuntary weight loss) | 783.21 |
| Carcinoid Syndrome | 259.2, 152., 153., and other malignant neoplasm codes |
| Interferon Alpha 2a, 2b | |
| Carcinoid Tumors | 152., 153., 154.0, 154.1, 162.2 to 162.9, 259.2 |
| Doxorubicin, ¹ Fluorouracil ¹ , Interferon Alpha 2a, 2b, Octreotide, Streptozocin | |
| Carcinoma of Unknown Primary Site | 190._ to 199.1 |
| Carboplatin, ¹ Cisplatin, ¹ Etoposide, ¹ Paclitaxel, ¹ | |
| Cervix | 180._ |
| Bleomycin, Carboplatin, ³ Cisplatin, Cyclophosphamide, ¹ Doxorubicin, Fluorouracil, Hydroxyurea, Ifosfamide, Irinotecan Hydrochloride ³ XX, Methotrexate, ¹ Mitomycin, Paclitaxel, Uracil Mustard, ³ Vincristine, ¹ Vinorelbine Tartrate | |
| Chronic Anemia (associated with malignancy) | 285.9 |
| Darbepoetin Alfa, ¹ Epoetin Alfa | |
| Chronic Lymphocytic Leukemia | 204.1_ |
| Alemtuzumab, Chlorambucil, Cladribine, ¹ Cyclophosphamide, Dexamethasone, Doxorubicin, ¹ Fludarabine Phosphate, Interferon Alpha 2a, 2b, ³ Mechlorethamine, Pentostatin, Prednisone, Rituximab, ¹ Sodium Phosphate P 32, ¹ Uracil Mustard, Vincristine | |
| Chronic Myelocytic Leukemia | 205.1_ |
| Aldesleukin, ¹ Busulfan, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, ³ Etoposide, ³ Hydroxyurea, Imatinib Mesylate, Interferon Alpha 2a, 2b, Mechlorethamine, Melphalan, Mercaptopurine, Mitomycin, ¹ Prednisone, ³ Sodium Phosphate P 32, ¹ Thioguanine, Topotecan, ¹ Uracil Mustard, Vincristine ¹ | |
| Chronic Myelomonocytic Leukemia | 205.10 |
| Daunorubicin, Mitomycin, Topotecan ¹ | |
| Colorectal | 153., 154._ |
| Bevacizumab, Capecitabine, Carmustine, ³ Cetuximab, [†] Floxuridine, Fluorouracil, Irinotecan Hydrochloride, Leucovorin, Levamisole, Lomustine, Methotrexate, ¹ Mitomycin, Oxaliplatin, Raltitrexed (not available in US), ¹ Streptozocin, ¹ Trimetrexate, ¹ Vincristine ¹ | |
| Cutaneous T-Cell Lymphoma | 202.1., 202.2., 202.8_ |
| Bexarotene, Carmustine, ³ Chlorambucil, ¹ ★Cladribine, ³ Denileukin, Difitox, Etoposide, ¹ Fludarabine Phosphate ³ , Interferon Alpha 2a, 2b, Mechlorethamine, ¹ Methotrexate, ³ Pentostatin ¹ , Vinblastine, Vincristine ¹ | |
| Endometrial | 182.0 |
| Cisplatin, Carboplatin, ¹ Cyclophosphamide, ¹ Dactinomycin, ¹ Doxorubicin, Etoposide, ¹ Fluorouracil, Goserelin, Hydroxyprogesterone, ³ Ifosfamide, ¹ Leuprolide (endometriosis, endometriotic lesions, only), Medroxyprogesterone, Megestrol, Melphalan ¹ , Methoxsalen, Paclitaxel, Tamoxifen ¹ | |

Indication Index

| AGENT/Indication(s) | ICD-9 Code(s) | INDICATION/Agent(s) | ICD-9 Code(s) |
|---|-------------------------------------|--|------------------|
| Esophagus | 150._ | Lung (Small and/or Non-Small Cell) | 162._ |
| Bleomycin, ¹ Carboplatin, ¹ Cisplatin, Docetaxel, ¹ Doxorubicin, ¹ Epirubicin Hydrochloride, ¹ Fluorouracil, Interferon 2a, ¹ Methotrexate, ¹ Mitomycin, ¹ Paclitaxel, Porfimer Sodium ¹ | | Altretamine, ¹ Amifostine, Bevacizumab ¹ , Carboplatin, Cisplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin Hydrochloride, ¹ Erlotinib Hydrochloride, Etoposide, Etoposide Phosphate, Fluorouracil, Gefitinib, Gemcitabine Hydrochloride, Irinotecan, ^{1,3} Ifosfamide, Lomustine, Mechlorethamine, Methotrexate, Mitomycin, Paclitaxel, Pemetrexed, Porfimer Sodium, ¹ Procarbazine, Topotecan, Uracil Mustard, ³ Vinblastine, Vincristine, Vinorelbine Tartrate | |
| Ewing's Sarcoma | 170._ | Malignant Peritoneal Effusion | 197.6 |
| Cyclophosphamide, Dactinomycin, Daunorubicin, ¹ Doxorubicin, Etoposide, Ifosfamide, Leucovorin, ¹ Vincristine | | Bleomycin, ¹ Chromic Phosphate P32, ¹ Mechlorethamine, Thiotepa | |
| Fallopian Tube | 183.2 | Malignant Pleural Effusion | 197.2 |
| Carboplatin, ¹ Cisplatin, ¹ Paclitaxel ¹ | | Bleomycin, Chromic Phosphate P32, ¹ Mechlorethamine, Thiotepa | |
| Gallbladder | 156._ | Mantle Cell Lymphoma | 202.80 |
| Gemcitabine ¹ , Mitomycin ¹ | | Bortezomib ¹ | |
| Hairy Cell Leukemia | 202.4_ | Melanoma | 172._ |
| Chlorambucil, Cladribine, Fludarabine Phosphate, ³ Interferon Alpha 2a, 2b, Pentostatin | | Aldesleukin, Amifostine, Asparaginase ¹ (melanosarcoma), Bleomycin, ¹ Carboplatin, ¹ Carmustine, Cisplatin, Dacarbazine, Hydroxyurea, Interferon Alpha 2a, 2b, Lomustine, ¹ Melphalan, Tamoxifen, ¹ Temozolomide, ¹ Thalidomide ³ XX, Vinblastine, Vincristine ¹ | |
| Head & Neck | 140._ to 149._, 160._, 161._, 195.0 | Mesothelioma | 163._ |
| Amifostine, Bleomycin, Carboplatin, Cetuximab, ¹ Cisplatin, Cyclophosphamide, ³ Docetaxel, ¹ Doxorubicin, Fluorouracil, ¹ Hydroxyurea, ³ Ifosfamide, ¹ Leucovorin, ¹ Methotrexate, Mitomycin, Paclitaxel, Vinblastine | | Cisplatin, ³ Pemetrexed [†] | |
| Hemorrhagic Cystitis | 595.82, 995.2 | Multiple Myeloma | 203.0_ |
| Mesna (Cyclophosphamide-induced, Ifosfamide-induced) | | Bortezomib, Carmustine, Cyclophosphamide, Dexamethasone, ¹ Doxorubicin, Doxorubicin Liposomal, ¹ Etoposide, ¹ Interferon Alpha 2a, 2b, Lomustine, ¹ Melphalan, Pamidronate Disodium, Prednisone, ¹ Procarbazine, ¹ Thalidomide, Vincristine, Zoledronic Acid ¹ | |
| Hodgkin's Lymphoma | 201._ _ | Myelodysplastic Syndromes | 238.7 |
| Amifostine, Bleomycin, Carboplatin, ¹ Carmustine, Chlorambucil, Cisplatin, Cyclophosphamide, Cytarabine, ¹ Dacarbazine, Dexamethasone, Doxorubicin, Epirubicin Hydrochloride, ¹ Etoposide, Gemcitabine Hydrochloride, ¹ Ifosfamide, ¹ Lomustine, Mechlorethamine, Melphalan, ¹ Mercaptopurine, ³ Methotrexate, ¹ Prednisone, Procarbazine, Thiotepa, ¹ Uracil Mustard, ³ Vinblastine, Vincristine | | Amifostine, ¹ Azacitidine, Cytarabine, ¹ Epoetin Alfa, Filgrastim, ★Lenalidomide, [†] Sargramostim, Topotecan Hydrochloride ¹ | |
| Hypercalcemia (associated with malignancy) | 275.42 | Neuroblastoma | 160._, 194.0 |
| Corticotropin, ¹ Dexamethasone, Etidronate, Gallium Nitrate, Hydrocortisone, ¹ Pamidronate, Plicamycin, Prednisone, Plicamycin, Zoledronic Acid ³ | | Cisplatin, ¹ Carboplatin, ³ XX Cyclophosphamide, Dacarbazine, ³ Daunorubicin, ¹ Doxorubicin, Etoposide, Ifosfamide, ¹ Teniposide, ¹ Vinblastine, ¹ Vincristine | |
| Kaposi's Sarcoma | 176._ | Neutropenia | 288.0 |
| Alitretinoin, Bexarotene, Bleomycin, Cisplatin, ¹ Dactinomycin, ¹ Daunorubicin Liposomal, Doxorubicin, Doxorubicin Liposomal, Etoposide, Interferon Alpha 2a, 2b, Paclitaxel, Thalidomide ³ XX, Vinblastine, Vincristine | | Filgrastim (Chemotherapy-induced, assoc. with bone marrow transplant), Pegfilgrastim, Sargramostim (assoc. with bone marrow transplant, chemotherapy-induced, including chemotherapy assoc. with acute myelogenous leukemia) | |
| Kidney | 189.0, 189.1 | Non-Hodgkin's Lymphoma | 200._ _, 202._ _ |
| Aldesleukin, Amifostine, Cisplatin, ³ Cyclophosphamide, ¹ Fluorouracil, ³ XX Floxuridine, ¹ Interferon Alpha 2a, 2b, Medroxyprogesterone, ★Sarafenib Tosylate, ¹ ★Sunitinib, [†] Thalidomide, ³ Vinblastine, Vincristine | | Amifostine, Asparaginase, Bleomycin, Carboplatin, ¹ Carmustine, Chlorambucil, Cisplatin, Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, ¹ Dexamethasone, ³ Doxorubicin, Epirubicin Hydrochloride, ¹ Etoposide, Fludarabine Phosphate, Gemcitabine Hydrochloride, ¹ Ibritumomab tiuxetan, Ifosfamide, Interferon Alpha 2a, 2b, Leucovorin, ¹ Mechlorethamine, Mercaptopurine, Methotrexate, Mitoxantrone, ¹ Prednisone, Procarbazine, Rituximab, Teniposide, ¹ Tositumomab, Iodine I-131, Uracil Mustard, Vinblastine, Vincristine | |
| Liver | 155.0, 155.2 | | |
| Cisplatin, Doxorubicin, ¹ Etoposide, Floxuridine, Fluorouracil, Mitoxantrone, ¹ Vincristine ¹ | | | |

Indication Index

| AGENT/Indication(s) | ICD-9 Code(s) |
|---|------------------------------|
| Osteosarcoma | 170., 198.5 (secondary code) |
| Bleomycin, Cisplatin, Cyclophosphamide, ¹ Dactinomycin, Doxorubicin, Etoposide, ¹ Ifosfamide, Leucovorin, Melphalan, ³ Methotrexate, Vincristine, Zoledronic Acid ¹ | |
| Ovary | 183.0 |
| Altretamine, ¹ Amifostine, Carboplatin, Chlorambucil, Chromic Phosphate P 32, ¹ Cisplatin, Cyclophosphamide, Dactinomycin, ³ Docetaxel, ¹ Doxorubicin, Doxorubicin Liposomal, Epirubicin Hydrochloride, ¹ Etoposide, Floxuridine, Fluorouracil, Gemcitabine, Hydroxyurea, ¹ Ifosfamide, Interferon Alpha 2a, 2b, ³ Melphalan, Methotrexate, ¹ Paclitaxel, Thalidomide ³ ^{XX} , Thiotepa, Topotecan Hydrochloride, Treosulfan, ¹ Uracil Mustard, ³ Vinorelbine ¹ | |
| Ovary (Germ Cell) | 183.9 |
| Bleomycin, Chlorambucil, Cisplatin, Cyclophosphamide, Dactinomycin, ¹ Doxorubicin, Doxorubicin Liposomal, ¹ Etoposide, ¹ Ifosfamide ¹ Vinblastine, ¹ Vincristine ¹ | |
| Pancreas | 157._ |
| Dacarbazine, Doxorubicin, ¹ ★Erlotinib Hydrochloride, Fluorouracil, Gemcitabine Hydrochloride, Ifosfamide, ¹ Methotrexate, ¹ Mitomycin, Octreotide | |
| Paget's Disease of Bone | 731.0 |
| Etidronate, Pamidronate, Plicamycin | |
| Penis | 187.1 to 187.4 |
| Bleomycin, Cisplatin ³ ^{XX} , Fluorouracil, ¹ Methotrexate ¹ | |
| Peritoneal | 158.8, 158.9, 197.6 |
| Carboplatin, ¹ Cisplatin, ¹ Paclitaxel ¹ | |
| Prostate | 185 |
| Abarelix, Aminoglutethimide, ¹ Bicalutamide, Buserelin, ¹ Chlorotrianisene Chromic Phosphate P 32, ¹ Cisplatin, Cyclophosphamide, Dexamethasone, ¹ Diethylstilbestrol, Docetaxel, Doxorubicin, Estradiol, Estradiol Valerate, Estramustine, Estrogens (Conjugated & Esterified), Estrone, Ethinyl Estradiol, Fluorouracil, ¹ Flutamide, Goserelin, Ketoconazole, Leuprolide, Melphalan, ³ Mitoxantrone, Nilutamide, Paclitaxel, ¹ Prednisone, ¹ Thalidomide ³ ^{XX} , Triptorelin Pamoate, ³ Vinblastine ¹ | |
| Retinoblastoma | 190.5 |
| Carboplatin, Cisplatin, ¹ Cyclophosphamide, Doxorubicin, ¹ Etoposide, ¹ Vincristine ¹ | |
| Skin | 173._ |
| Bleomycin, Cisplatin, ¹ Fluorouracil, Interferon Alpha 2a, 2b, Masoprocol, Methoxsalen ¹ | |
| Soft-Tissue Sarcomas | 171._ |
| Bleomycin, ¹ Cisplatin, Cyclophosphamide, Dacarbazine, Dactinomycin, ³ Daunorubicin, ¹ Doxorubicin, Epirubicin Hydrochloride, ¹ Etoposide, Ifosfamide, Melphalan, ³ Methotrexate, ¹ Vinblastine, ¹ Vincristine | |
| Squamous Cell Carcinomas of Skin | 173._ |
| Bleomycin | |

| AGENT/Indication(s) | ICD-9 Code(s) |
|--|----------------------------|
| Stomach | 151._ |
| Carmustine, ¹ Cisplatin, Docetaxel, ¹ Doxorubicin, Epirubicin Hydrochloride, ¹ Etoposide, ¹ Fluorouracil, Imatinib Mesylate ¹ (GIST), Methotrexate, ¹ Mitomycin, Paclitaxel ¹ | |
| Testes | 186._ |
| Bleomycin, Carboplatin, Cisplatin, Cyclophosphamide, Dactinomycin, Doxorubicin, Etoposide, Etoposide Phosphate, Gemcitabine, Ifosfamide, Melphalan, ³ Paclitaxel, ¹ Plicamycin, Vinblastine | |
| Thymoma | 164.0, 164.8 |
| Cisplatin, Cyclophosphamide, ¹ Doxorubicin, ¹ Etoposide, ¹ Ifosfamide ¹ | |
| Thyroid | 193 |
| Bleomycin, ¹ Cisplatin, Doxorubicin, Levothyroxine, Liothyronine, Liotrix, Sodium Iodide I 131, ¹ Thyroglobulin, Thyroid, Thyrotropin | |
| Trophoblastic Neoplasms | 181, 236.1, 186.9 |
| Bleomycin, Cisplatin, Cyclophosphamide, ¹ Dactinomycin, Doxorubicin, ¹ Etoposide, Leucovorin, ¹ Methotrexate, Vinblastine, Vincristine ¹ | |
| Uterus | 182._ |
| Amifostine, Hydroxyprogesterone, Ifosfamide ³ ^{XX} | |
| Vulva | 184.1, 184.2, 184.3, 184.4 |
| Bleomycin | |
| Wilms' Tumor | 189.0 |
| Carboplatin ³ , Cisplatin, ¹ Cyclophosphamide, Dactinomycin, Daunorubicin, ¹ Doxorubicin, Etoposide, Ifosfamide, Vincristine | |

MOVING? DON'T MISS A SINGLE ISSUE!

Remember to let us know. Just fill out the form below and mail or fax it with your old mailing label to the Association of Community Cancer Centers, 11600 Nebel St., Suite 201, Rockville, MD 20852. Fax: 301-770-1949

| | | | |
|-------------|-------|----------|-----------|
| First | M.I. | Last | Degree(s) |
| <hr/> | | | |
| Title | | | |
| <hr/> | | | |
| Affiliation | | | |
| <hr/> | | | |
| Address | | | |
| <hr/> | | | |
| City | State | Zip Code | |
| <hr/> | | | |
| Phone | Fax | | |
| <hr/> | | | |
| E-mail | | | |
| <hr/> | | | |